Prophylactic IV immunoglobulin supplementation reduced the risk for severe infections by 90% among adults receiving a B-cell maturation antigen-directed bispecific antibody for treatment of multiple myeloma, study results showed.
The findings — published in Blood Cancer Discovery — appear to support International Myeloma Working Group (IMWG) guidelines recommending routine use of IV immunoglobulin supplementation for all patients receiving B-cell maturation antigen (BCMA)-directed bispecifics and who have IgG levels “All patients
